Benralizumab (anti-IL5Rα) depletes gut tissue eosinophilia and improves symptoms in hypereosinophilic syndrome with gastrointestinal involvement

Methods Twenty symptomatic HES subjects on stable background therapy with persistent eosinophilia (AEC >=1000 cells/mm3) were enrolled in a phase 2 double-blind placebo-controlled trial of benralizumab. Post-treatment at week 24, AEC was 0 cells/mm3 in all subjects and endoscopies demonstrated dr...

Full description

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 141; no. 2; p. AB196
Main Authors Kuang, Fei Li, Alao, Hawaa, Kumar, Sheila, Powers, Astin, Quezado, Martha, Wang, Zengfeng, Ware, JeanAnne, Wetzler, Lauren, Brown, Thomas, Khoury, Paneez, Klion, Amy D.
Format Journal Article
LanguageEnglish
Published St. Louis Elsevier Inc 01.02.2018
Elsevier Limited
Subjects
Blood diseases
Eosinophilia
Immunosuppressive agents
Leukocytes (eosinophilic)
Monoclonal antibodies
Online AccessGet full text

Cover

More Information
Summary:Methods Twenty symptomatic HES subjects on stable background therapy with persistent eosinophilia (AEC >=1000 cells/mm3) were enrolled in a phase 2 double-blind placebo-controlled trial of benralizumab. Post-treatment at week 24, AEC was 0 cells/mm3 in all subjects and endoscopies demonstrated dramatic depletion of eosinophils: median 0 eos/hpf in all upper GI segments (range 0-3 eos/hpf, n=7) and colon (range 0-1 eos/hpf, n=5).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2017.12.622